Shanghai Fudan Forward S&T Co., Ltd

SHSE:600624 Stock Report

Market Cap: CN¥4.2b

Shanghai Fudan Forward S&T Valuation

Is 600624 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600624 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 600624's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 600624's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600624?

Key metric: As 600624 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600624. This is calculated by dividing 600624's market cap by their current revenue.
What is 600624's PS Ratio?
PS Ratio6.5x
SalesCN¥638.98m
Market CapCN¥4.16b

Price to Sales Ratio vs Peers

How does 600624's PS Ratio compare to its peers?

The above table shows the PS ratio for 600624 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
002082 Wanbangde Pharmaceutical Holding Group
2.3xn/aCN¥3.7b
003020 Hefei Lifeon Pharmaceutical
2.5x17.7%CN¥3.7b
688356 Jenkem Technology
14.7x22.3%CN¥3.4b
603222 Chimin Health Management
4.4xn/aCN¥4.0b
600624 Shanghai Fudan Forward S&T
6.5xn/aCN¥4.2b

Price-To-Sales vs Peers: 600624 is expensive based on its Price-To-Sales Ratio (6.5x) compared to the peer average (6x).

Price to Sales Ratio vs Industry

How does 600624's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.28b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$777.77m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$410.69m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
600624 6.5xIndustry Avg. 3.5xNo. of Companies35PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 600624 is expensive based on its Price-To-Sales Ratio (6.5x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 600624's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600624 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600624's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

7D

2.2%

1Y

7.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

7D

-2.4%

1Y

12.8%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.91

7D

-1.8%

1Y

14.6%